miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer

Abstract

Dysregulation of PI3K and MAPK pathways promotes uncontrolled cell proliferation, apoptotic inhibition and metastasis. Individual targeting of these pathways using kinase inhibitors has largely been insufficient due to the existence of cross-talks between these parallel cascades. MicroRNAs are small non-coding RNAs targeting several genes simultaneously and controlling cancer-related processes. To identify miRNAs repressing both PI3K and MAPK pathways in breast cancer, we re-analyzed our previous miRNA mimic screen data with reverse phase protein array (RPPA) output, and identified miR-564 inhibiting both PI3K and MAPK pathways causing markedly decreased cell proliferation through G1 arrest. Moreover, ectopic expression of miR-564 blocks epithelial-mesenchymal transition (EMT) and reduces migration and invasion of aggressive breast cancer cells. Mechanistically, miR-564 directly targets a network of genes comprising AKT2, GNA12, GYS1 and SRF, thereby facilitating simultaneous repression of PI3K and MAPK pathways. Notably, combinatorial knockdown of these target genes using a cocktail of siRNAs mimics the phenotypes exerted upon miR-564 expression. Importantly, high miR-564 expression or low expression of target genes in combination is significantly correlated with better distant relapse-free survival of patients. Overall, miR-564 is a potential dual inhibitor of PI3K and MAPK pathways, and may be an attractive target and prognostic marker for breast cancer.

Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma

“…When taking all of these considerations together, our data suggest that silencing any two of the three target genes is better than silencing any one, and that silencing all three genes is better than silencing any two. Similar multi‐component strategies have been successfully employed to treat several other types of cancer, suggesting that LNPs could have broad applicability for cancer treatment.…”

Phenotypic functional activities of monocyte change during crosstalk with breast cancer cell and enhancing effect of metformin of IFN-γ-associated antitumor cytokine production

“…In terms of cell activation and proliferation, the PI3K/Akt/mTOR signaling pathway has been highlighted to play an important role in vital cell functions including cell growth, proliferation, differentiation and survival (39). Its hyper-activation can lead to excessive tumor cell proliferation, inhibition of apoptosis, angiogenesis, invasion and metastasis (40)(41)(42). For our part, we suggest that MET treatment may play a noticeable role in modulating cell signaling activation related to PI3K/Akt/mTOR pathways in breast cancer cells, that corroborates recent reports (43,44).…”

Manganese‐12 acetate suppresses the migration, invasion, and epithelial–mesenchymal transition by inhibiting Wnt/β‐catenin and PI3K/AKT signaling pathways in breast cancer cells

“…Leptin was reported to promote the breast cancer cells EMT by activating the PI3K/AKT signaling pathway . miR‐564 could directly target the AKT2 and inhibit the PI3K/AKT pathway, and further inhibit the EMT process, proliferation, and invasion of breast cancer . Xie et al found that FYN was transcriptionally regulated by FOXO1, and mediated FGF2‐induced EMT through both the PI3K/AKT and ERK signaling pathways .…”